Keywords: USA, FDA, Arena, Eisai, Lorcaserin, Obesity, Lorqess

In another disappointment for obesity drug candidates, US FDA declines to approve Arena/Eisai’s lorcaserin

Article | 25 October 2010

Print This

In yet another negative ruling for obesity drugs, the US Food and Drug Administration issued a Complete Response Letter (CRL) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in